Role of mu- and delta-opioid receptors in the nucleus accumbens in turning behaviour of rats. 2004

Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
Department of Dental Anaesthesiology, Nihon University School of Dentistry, Tokyo 101-8310, Japan.

The role of mu-, delta1- and delta2-opioid receptors in the nucleus accumbens in pivoting was investigated in freely moving rats. Unilateral injections of the mu-opioid receptor agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO, 1 and 2 microg) and the delta2-opioid receptor agonist, deltorphin II (1 and 2 microg), but not the delta1-opioid receptor agonist, [D-Pen(2,5)]-enkephalin (DPDPE, 1-4 microg), into the shell or the core of the nucleus accumbens significantly induced contraversive pivoting. The pivoting induced by DAMGO (2 microg) and deltorphin II (2 microg) was inhibited significantly by the mu-opioid receptor antagonist, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Phe-Thr-NH2 (CTOP, 0.1 and 1 microg), and the delta2-opioid receptor antagonist, naltriben (NTB, 0.1 and 1 mg/kg, i.p.), respectively. The DAMGO (2 microg)- or deltorphin II (2 microg)-induced pivoting was also inhibited significantly by co-administration of the dopamine D1/D2 receptor antagonist, cis(Z)-flupentixol (1 and 10 microg). The pivoting induced by unilateral injections of a mixture of dopamine D1 (SKF 38393, 5 microg) and D2 (quinpirole, 10 microg) receptor agonists into the shell was significantly inhibited by cis(Z)-flupentixol (1 and 10 microg) or NTB (1 and 3 mg/kg, i.p.), but not CTOP (1 microg) or delta1-opioid receptor antagonist, (E)-7-benzylidenenaltrexone (1 mg/kg, i.p.). The contraversive pivoting elicited by the cholinergic agonist, carbachol (5 microg), into the core was inhibited by co-administration of the muscarinic M1 antagonist, pirenzepine (1 microg), but not cis(Z)-flupentixol (1 microg). The results suggest that unilateral activation of mu- or delta2-opioid, but not delta1-opioid, receptors in the core and/or shell of the nucleus accumbens elicits contraversive pivoting that requires intact dopamine D1/D2 receptors in the shell, but not intact muscarinic M1 mechanism in the core. The study also shows that delta2-opioid, but not mu- and delta1-opioid, receptors in the core and/or shell modulate the shell-specific, dopamine D1/D2 receptor mechanisms involved in the production of pivoting.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009714 Nucleus Accumbens Collection of pleomorphic cells in the caudal part of the anterior horn of the LATERAL VENTRICLE, in the region of the OLFACTORY TUBERCLE, lying between the head of the CAUDATE NUCLEUS and the ANTERIOR PERFORATED SUBSTANCE. It is part of the so-called VENTRAL STRIATUM, a composite structure considered part of the BASAL GANGLIA. Accumbens Nucleus,Nucleus Accumbens Septi,Accumbens Septi, Nucleus,Accumbens Septus, Nucleus,Accumbens, Nucleus,Nucleus Accumbens Septus,Nucleus, Accumbens,Septi, Nucleus Accumbens,Septus, Nucleus Accumbens
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012399 Rotation Motion of an object in which either one or more points on a line are fixed. It is also the motion of a particle about a fixed point. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Clinorotation,Clinorotations,Rotations
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D017450 Receptors, Opioid, mu A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine. Morphine Receptors,Opioid Receptors, mu,Receptors, Morphine,Receptors, mu,Receptors, mu Opioid,mu Receptors,Morphine Receptor,mu Opioid Receptor,mu Receptor,Opioid Receptor, mu,Receptor, Morphine,Receptor, mu,Receptor, mu Opioid,mu Opioid Receptors
D017465 Receptors, Opioid, delta A class of opioid receptors recognized by its pharmacological profile. Delta opioid receptors bind endorphins and enkephalins with approximately equal affinity and have less affinity for dynorphins. Opioid Receptors, delta,Receptors, delta,Receptors, delta Opioid,delta Receptors,delta Opioid Receptor,delta Receptor,Opioid Receptor, delta,Receptor, delta,Receptor, delta Opioid,delta Opioid Receptors

Related Publications

Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
July 2009, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
March 2008, Neuropharmacology,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
June 2008, Current drug abuse reviews,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
September 2000, Brain research,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
January 2003, Neuropharmacology,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
January 2005, Neuroscience,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
August 1995, Psychopharmacology,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
January 1999, Neuroscience,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
May 2006, Neuroscience letters,
Satoshi Matsuzaki, and Hiroko Ikeda, and Gaku Akiyama, and Michiko Sato, and Shoko Moribe, and Tsutomu Suzuki, and Hiroshi Nagase, and Alexander R Cools, and Noriaki Koshikawa
January 1994, Reviews in the neurosciences,
Copied contents to your clipboard!